reserpine has been researched along with Parkinson Disease, Secondary in 70 studies
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 7.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| "Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and Drug Administration for the treatment of chorea in Huntington's disease." | 6.46 | Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. ( Guay, DR, 2010) |
| "This is a review of reserpine, haloperidol, and various phenothiazines that produce parkinsonism and other movement disorders." | 4.78 | Drug-induced parkinsonism and other movement disorders. ( Ross, RT, 1990) |
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 3.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| "Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and Drug Administration for the treatment of chorea in Huntington's disease." | 2.46 | Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. ( Guay, DR, 2010) |
| "Reserpine (RES) is an irreversible inhibitor of VMAT2 used to study Parkinson's disease (PD) and screening for antiparkinsonian treatments in rodents." | 1.62 | Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): Implications for cognitive deficits in a progressive animal model for Parkinson's disease. ( Abílio, VC; Conceição, IM; Freitas, TA; Izídio, GS; Leão, AHFF; Medeiros, AM; Meurer, YSR; Ribeiro, AM; Silva, RH, 2021) |
| "Reserpine treatment elongated the striatal neuronal cilia in D1-null mice but not in D2-null mice." | 1.40 | Lack of dopaminergic inputs elongates the primary cilia of striatal neurons. ( Asanuma, M; Kasahara, K; Katayama, T; Kumamoto, N; Matsuzaki, S; Miyazaki, I; Miyoshi, K; Murakami, S; Sasaoka, T; Sato, A; Takeshima, M, 2014) |
| "Haloperidol-induced catalepsy was inhibited by the Merz glycine site antagonists MRZ 2/570, MRZ 2/571 and MRZ 2/576 but not by another antagonist L-701,324 or the glycine site partial agonists ACPC and D-CS." | 1.30 | GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. ( Danysz, W; Karcz-Kubicha, M; Lorenz, B, 1999) |
| "Dextromethorphan has been reported to be a weak antagonist of the ion channel associated with the NMDA receptor, and to have putative antiparkinsonian activity in man." | 1.29 | Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. ( Kaur, S; Starr, MS, 1995) |
| "Remacemide hydrochloride is an anticonvulsant, neuroprotective compound with antagonist activity at the N-methyl-D-aspartate receptor ion channel." | 1.29 | Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. ( Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (51.43) | 18.7374 |
| 1990's | 19 (27.14) | 18.2507 |
| 2000's | 4 (5.71) | 29.6817 |
| 2010's | 8 (11.43) | 24.3611 |
| 2020's | 3 (4.29) | 2.80 |
| Authors | Studies |
|---|---|
| Olaya, MDP | 1 |
| Vergel, NE | 1 |
| López, JL | 1 |
| Viña, MD | 1 |
| Guerrero, MF | 1 |
| Pregeljc, D | 1 |
| Teodorescu-Perijoc, D | 1 |
| Vianello, R | 1 |
| Umek, N | 1 |
| Mavri, J | 1 |
| Cintra, RR | 1 |
| Lins, LCRF | 1 |
| Medeiros, KAAL | 1 |
| Souza, MF | 1 |
| Gois, AM | 1 |
| Bispo, JMM | 2 |
| Melo, MS | 1 |
| Leal, PC | 1 |
| Meurer, YSR | 2 |
| Ribeiro, AM | 5 |
| Silva, RH | 5 |
| Marchioro, M | 1 |
| Santos, JR | 4 |
| Leão, AHFF | 2 |
| Freitas, TA | 1 |
| Medeiros, AM | 2 |
| Abílio, VC | 3 |
| Izídio, GS | 3 |
| Conceição, IM | 1 |
| Beserra-Filho, JIA | 1 |
| de Macêdo, AM | 1 |
| de Oliveira-Melo, AJ | 1 |
| Menezes, PDP | 1 |
| Duarte, MC | 1 |
| de Souza Araújo, AA | 1 |
| Quintans-Júnior, LJ | 1 |
| Cunha, JA | 1 |
| Dierschnabel, AL | 1 |
| Campêlo, CL | 1 |
| Leão, AH | 2 |
| Silva, AF | 1 |
| Engelberth, RC | 1 |
| Cavalcante, JS | 1 |
| Miyoshi, K | 1 |
| Kasahara, K | 1 |
| Murakami, S | 1 |
| Takeshima, M | 1 |
| Kumamoto, N | 1 |
| Sato, A | 1 |
| Miyazaki, I | 1 |
| Matsuzaki, S | 1 |
| Sasaoka, T | 1 |
| Katayama, T | 1 |
| Asanuma, M | 1 |
| Ouattara, B | 1 |
| Gasparini, F | 1 |
| Morissette, M | 1 |
| Grégoire, L | 1 |
| Samadi, P | 1 |
| Gomez-Mancilla, B | 1 |
| Di Paolo, T | 1 |
| Guay, DR | 1 |
| Fernandes, VS | 1 |
| Melo, TG | 1 |
| Cabral, A | 1 |
| Ribeiro, RA | 1 |
| Sutton, AC | 1 |
| Yu, W | 1 |
| Calos, ME | 1 |
| Smith, AB | 1 |
| Ramirez-Zamora, A | 1 |
| Molho, ES | 1 |
| Pilitsis, JG | 1 |
| Brotchie, JM | 8 |
| Shin, DS | 1 |
| Murray, TK | 1 |
| Messenger, MJ | 1 |
| Ward, MA | 1 |
| Woodhouse, S | 1 |
| Osborne, DJ | 1 |
| Duty, S | 2 |
| O'Neill, MJ | 1 |
| Wang, W | 1 |
| Zhao, DZ | 1 |
| Sun, XF | 1 |
| Gu, SD | 1 |
| Atadzhanov, M | 1 |
| Balldin, J | 1 |
| Granérus, AK | 1 |
| Lindstedt, G | 1 |
| Modigh, K | 1 |
| Wålinder, J | 1 |
| Fahn, S | 1 |
| Torrini, M | 1 |
| Masini, E | 1 |
| Ledda, F | 1 |
| Mannaioni, PF | 1 |
| Johnels, B | 1 |
| Steg, G | 2 |
| Maneuf, YP | 3 |
| Mitchell, IJ | 4 |
| Crossman, AR | 5 |
| Woodruff, GN | 2 |
| Kaur, S | 1 |
| Starr, MS | 1 |
| Lawson, S | 1 |
| Moser, B | 1 |
| Laidlaw, SM | 1 |
| Cooper, AJ | 1 |
| Walkinshaw, G | 1 |
| Waters, CM | 1 |
| Greenamyre, JT | 1 |
| Eller, RV | 1 |
| Zhang, Z | 1 |
| Ovadia, A | 1 |
| Kurlan, R | 1 |
| Gash, DM | 1 |
| Ossowska, K | 1 |
| Lorenc-Koci, E | 2 |
| Schulze, G | 1 |
| Wolfarth, S | 2 |
| Salamone, J | 1 |
| Baskin, P | 1 |
| Hughes, NR | 1 |
| McKnight, AT | 1 |
| Hill, MP | 3 |
| Huang, KX | 1 |
| Bergstrom, DA | 1 |
| Ruskin, DN | 1 |
| Walters, JR | 1 |
| Nash, JE | 1 |
| Karcz-Kubicha, M | 1 |
| Lorenz, B | 1 |
| Danysz, W | 1 |
| Obata, T | 1 |
| Tolwani, RJ | 1 |
| Jakowec, MW | 1 |
| Petzinger, GM | 1 |
| Green, S | 1 |
| Waggie, K | 1 |
| Dawson, L | 1 |
| Chadha, A | 1 |
| Megalou, M | 1 |
| Poyot, T | 1 |
| Condé, F | 1 |
| Grégoire, MC | 1 |
| Frouin, V | 1 |
| Coulon, C | 1 |
| Fuseau, C | 1 |
| Hinnen, F | 1 |
| Dollé, F | 1 |
| Hantraye, P | 1 |
| Bottlaender, M | 1 |
| Gründig, E | 1 |
| Raheem, KA | 1 |
| Salvenmoser, F | 1 |
| Schedl, R | 1 |
| Weiss, J | 1 |
| Diamond, BI | 2 |
| Borison, RL | 2 |
| Halbhübner, K | 1 |
| Herken, H | 1 |
| Loos, D | 1 |
| Poirier, LJ | 1 |
| Marsden, CD | 1 |
| Duvoisin, RC | 1 |
| Jenner, P | 1 |
| Parkes, JD | 1 |
| Pycock, C | 1 |
| Tarsy, D | 1 |
| Arbuthnott, GW | 1 |
| Murray, LG | 1 |
| Heikkila, RE | 1 |
| Sonsalla, PK | 1 |
| Sambrook, MA | 1 |
| Ross, RT | 1 |
| Jankovic, J | 1 |
| Casabona, J | 1 |
| Rushkevich, IuE | 1 |
| Van Woert, MH | 1 |
| Sethy, VH | 1 |
| Ambani, LM | 1 |
| Whittier, JR | 1 |
| Korenyi, C | 1 |
| Velkov, VA | 2 |
| Chase, TN | 1 |
| Carlsson, A | 2 |
| Ditfurth, HV | 1 |
| Klawans, HL | 1 |
| Bordeleau, JM | 1 |
| Tétreault, L | 1 |
| Hornykiewicz, O | 1 |
| Horst, WD | 1 |
| Pool, WR | 1 |
| Spiegel, HE | 1 |
| Tret'iakova, KA | 2 |
| Samoĭlova, ZT | 2 |
| Morrison, AB | 1 |
| Webster, RA | 1 |
| Khaliutina, LV | 1 |
| Degkwitz, R | 2 |
| Sutherland, JM | 1 |
| Nose, T | 1 |
| Kojima, M | 1 |
| Ishida, R | 1 |
| Shintomi, K | 1 |
| Kowa, Y | 1 |
| Hornykiewicz, OD | 1 |
| Hassler, R | 1 |
| Bak, IJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo Controlled Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease[NCT00029666] | Phase 2 | 40 participants | Interventional | 2002-01-31 | Completed | ||
| Namenda as Prevention for Post-Operative Delirium[NCT00303433] | Phase 4 | 30 participants | Interventional | 2006-03-31 | Terminated | ||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for reserpine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Cytochrome P | 2010 |
[Modeling parkinsonism (review)].
Topics: Aluminum; Animals; Carbachol; Cats; Caudate Nucleus; Chlorides; Chlorpromazine; Disease Models, Anim | 1982 |
[Acute drug-induced extrapyramidal syndrome: case studies of a decade at the autonomous toxicology department of the Arcispedale].
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Benzamides; Butyrophenones; Child; Drug-Related Sid | 1981 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Met | 1999 |
The MPTP-treated mouse as a model of parkinsonism: how good is it?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Eval | 1992 |
Drug-induced parkinsonism and other movement disorders.
Topics: Haloperidol; Humans; Movement Disorders; MPTP Poisoning; Parkinson Disease, Secondary; Phenothiazine | 1990 |
Pathological aspects on Parkinson's syndrome.
Topics: Animals; Basal Ganglia; Basal Ganglia Diseases; Central Nervous System; Chlorpromazine; Corpus Stria | 1972 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
Biochemical and pharmacological aspects of Parkinsonism.
Topics: Animals; Blood-Brain Barrier; Brain; Central Nervous System; Chemoreceptor Cells; Chlorpromazine; Co | 1972 |
The pharmacology of parkinsonism (a review).
Topics: Acetylcholine; Animals; Atropa belladonna; Atropine; Central Nervous System; Chlorpromazine; Dextroa | 1968 |
Dopamine and extrapyramidal motor function and dysfunction.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Butyrophenones; Caudate Nucleus; Dihydroxyphenylalanin | 1972 |
[l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
Topics: Acetylcholine; Basal Ganglia; Butyrophenones; Chorea; Dihydroxyphenylalanine; Dopamine; Extrapyramid | 1969 |
Parkinson's syndrome: aetiological factors and certain clinical features.
Topics: Adult; Aged; Brain Injuries; Butyrophenones; Female; Humans; Intracranial Arteriosclerosis; Male; Me | 1971 |
1 trial available for reserpine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[Extrapyramidal symptoms during the use of neuroleptics].
Topics: Butyrophenones; Central Nervous System Stimulants; Clinical Trials as Topic; Extrapyramidal Tracts; | 1967 |
56 other studies available for reserpine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combina | 2019 |
How Important Is the Use of Cocaine and Amphetamines in the Development of Parkinson Disease? A Computational Study.
Topics: Amphetamine; Animals; Cocaine; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drosophila mel | 2020 |
Nociception alterations precede motor symptoms in a progressive model of parkinsonism induced by reserpine in middle-aged rats.
Topics: Animals; Disease Models, Animal; Dorsal Raphe Nucleus; Male; Motor Activity; Nociception; Parkinson | 2021 |
Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): Implications for cognitive deficits in a progressive animal model for Parkinson's disease.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine; Hippocampus; Male; Parkinson Disease | 2021 |
Eplingiella fruticosa leaf essential oil complexed with β-cyclodextrin produces a superior neuroprotective and behavioral profile in a mice model of Parkinson's disease.
Topics: Animals; Antioxidants; beta-Cyclodextrins; Corpus Striatum; Immunohistochemistry; Lamiaceae; Lipid P | 2019 |
Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Cognition; Data Interpretation, Statistical; Dyskinesia | 2013 |
Lack of dopaminergic inputs elongates the primary cilia of striatal neurons.
Topics: Animals; Astrocytes; Cell Shape; Cilia; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Dopamin | 2014 |
Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Autoradiography; Biogenic Amines; Brain Chemistry; Catecholamines; Ca | 2010 |
Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Avoidance Learning; Behavior, Animal; Disease Models, Animal; | 2012 |
Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat.
Topics: Animals; Antipsychotic Agents; Beta Rhythm; Deep Brain Stimulation; Forelimb; Hypokinesia; Male; Oxi | 2013 |
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease.
Topics: Amino Acids; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds, Heterocycli | 2002 |
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Dopamine; Drug Combinations; Drug Syner | 2002 |
Neuroendocrine evidence for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy.
Topics: Adult; Aged; Apomorphine; Clonidine; Depressive Disorder; Electroconvulsive Therapy; Female; Growth | 1982 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combinat | 1983 |
A mechanographic method for measurement of muscle tone in the conscious rat. The calf muscle stretch response in reserpine-induced rigidity.
Topics: Animals; Apomorphine; Biomechanical Phenomena; Disease Models, Animal; Haloperidol; Male; Muscle Con | 1982 |
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Arrhythmia Agents; Basal Ganglia; Benzof | 1995 |
Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Behavior, | 1995 |
Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat.
Topics: Animals; Apoptosis; Excitatory Amino Acid Antagonists; Glutamic Acid; Neostriatum; Neural Pathways; | 1994 |
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvuls | 1994 |
On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus.
Topics: Animals; Bicuculline; Corpus Striatum; Drug Combinations; Efferent Pathways; Enkephalins; gamma-Amin | 1994 |
The influence of dizocilpine (MK-801) on the reserpine-enhanced electromyographic stretch reflex in rats.
Topics: Animals; Dizocilpine Maleate; Dopamine; Electromyography; Excitatory Amino Acid Antagonists; Male; M | 1996 |
Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor.
Topics: Animals; Antipsychotic Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Jaw | 1996 |
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Benzazepines; Benzoxazines; Dopamine Agonists; gamma-Aminobutyric Acid; Loco | 1997 |
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.
Topics: alpha-Methyltyrosine; Animals; Antiparkinson Agents; Benzeneacetamides; Benzofurans; Dose-Response R | 1998 |
N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Corpus Striatum; | 1998 |
Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Corpus Striatum; Dizocilpine Maleate; Dose-Resp | 1999 |
GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Catalepsy; Cyclopentanes; Drug Evaluation, Prec | 1999 |
Reserpine prevents hydroxyl radical formation by MPP+ in rat striatum.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Rela | 1999 |
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
Topics: alpha-Methyltyrosine; Animals; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; | 1999 |
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzofurans; | 1999 |
The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Cyclopropanes; Dyskinesia, Drug-Induced; Glycine; In | 2000 |
Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Carbon Radioisotopes; | 2001 |
Drug-induced parkinsonism in the rat- a model for biochemical investigation of the parkinson-syndrome. III. The incorporation of D-glucose-14C(U) in amino acids of brain and liver from rats pretreated with reserpine or with phenothiazines.
Topics: Amino Acids; Animals; Antipsychotic Agents; Brain; Glucose; Glutamates; Glutamine; Glycine; Liver; M | 1976 |
A new putative neuroregulator of the extrapyramidal system.
Topics: Animals; Dextroamphetamine; Extrapyramidal Tracts; Haloperidol; Humans; Male; Methyltyrosines; Neuro | 1978 |
Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs.
Topics: 6-Aminonicotinamide; Animals; Antipsychotic Agents; Baclofen; Brain; Brain Chemistry; Bromocriptine; | 1978 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines | 1978 |
Dopaminergic agonists in animal models of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Cats; Disease Models, Animal; Haplorhini; L | 1975 |
Relationship between animal models and clinical parkinsonism.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Humans; Levodopa; Norepinephrine; Parkinson Diseas | 1975 |
Dopamine receptor agonists in psychiatric disease.
Topics: Bipolar Disorder; Dopamine; Humans; Parkinson Disease, Secondary; Piperazines; Piribedil; Receptors, | 1975 |
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Brain Mapping; Callitrichinae; D | 1991 |
Coexistent tardive dyskinesia and parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levo | 1987 |
[Age characteristics of the development of a reserpine model of parkinsonism in rats].
Topics: Aging; Animals; Caudate Nucleus; Dyskinesia, Drug-Induced; Globus Pallidus; Male; Parkinson Disease, | 1987 |
Effect of phenothiazines on central cholinergic activity.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Brain Chemistry; Chlorp | 1974 |
Effect of oral fluphenazine on Huntington's chorea.
Topics: Age Factors; Aged; Chronic Disease; Female; Fluphenazine; Humans; Huntington Disease; Male; Mental P | 1968 |
Gerontological changes of ATP content and K-Na-ATPase activity in rats brain.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Aging; Animals; Brain; Female; Male; Parkinson Di | 1973 |
On the effect of amantadine on ATP content and ATPase activity in brain and blood of rats.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Amantadine; Animals; Brain; Brain Chemistry; Dise | 1974 |
Basic concepts underlying recent developments in the field of Parkinson's disease.
Topics: Biogenic Amines; Brain; Dihydroxyphenylalanine; Disease Models, Animal; Humans; Parkinson Disease; P | 1971 |
[Study of extrapyramidal manifestations induced by neuroleptics].
Topics: Antiparkinson Agents; Chlorpromazine; Drug Synergism; Extrapyramidal Tracts; Fluphenazine; Haloperid | 1972 |
Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Blepharoptosis; Brain; | 1973 |
[The reserpine model of parkinsonism and changes in the metabolism of mediators].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Epinephrine; Male; Norepin | 1973 |
Drug-induced experimental Parkinsonism.
Topics: Animals; Atropine; Benztropine; Butyrophenones; Cats; Chlorpromazine; Dose-Response Relationship, Dr | 1973 |
[Effect of l-dopa on the development of reserpine parkinsonism and the metabolism of catecholamines in rats].
Topics: Animals; Brain Chemistry; Catecholamines; Dihydroxyphenylalanine; Drug Interactions; Male; Parkinson | 1973 |
[Pharmacological properties of 6,6,9-trimethyl-9-azabicyclo (3,3,1)non-3 beta-yl-alpha, alpha-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent].
Topics: Acetylcholine; Analgesics; Anesthetics, Local; Animals; Anticonvulsants; Barbiturates; Behavior, Ani | 1971 |
[Drug-induced Parkinson's syndrome].
Topics: Acetylcholinesterase; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Humans; Movement Disor | 1972 |
Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future.
Topics: Animals; Brain; Dihydroxyphenylalanine; Dopamine; Humans; Injections, Intraperitoneal; Injections, I | 1970 |
[Submicroscopic catecholamine stores as sites of attack of the psychopharmaca, reserpine and monoamine oxidase inhibitors].
Topics: Animals; Catecholamines; Caudate Nucleus; Dopamine Antagonists; Epinephrine; Extrapyramidal Tracts; | 1966 |